

Stephen R Walsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2786397/publications.pdf>

Version: 2024-02-01

37
papers

1,682
citations

279487

23
h-index

360668

35
g-index

40
all docs

40
docs citations

40
times ranked

2768
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
2	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. <i>Lancet</i> , The, 2018, 391, 563-571.	6.3	165
3	First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 240-247.	1.9	144
4	Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256.	1.9	98
5	Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. <i>Expert Review of Vaccines</i> , 2011, 10, 1221-1240.	2.0	77
6	Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention. <i>Annals of Internal Medicine</i> , 2016, 164, 313.	2.0	70
7	Safety and Immunogenicity of Modified Vaccinia Ankara (ACAM3000): Effect of Dose and Route of Administration. <i>Journal of Infectious Diseases</i> , 2010, 201, 1361-1370.	1.9	69
8	Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. <i>Journal of Infectious Diseases</i> , 2015, 211, 518-528.	1.9	60
9	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
10	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , the, 2020, 7, e688-e698.	2.1	58
11	Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. <i>JCI Insight</i> , 2016, 1, .	2.3	58
12	Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial. <i>Journal of Infectious Diseases</i> , 2013, 207, 1888-1897.	1.9	54
13	Avian Reovirus-Induced Syncytium Formation Is Independent of Infectious Progeny Virus Production and Enhances the Rate, but Is Not Essential, for Virus-Induced Cytopathology and Virus Egress. <i>Virology</i> , 1996, 224, 453-464.	1.1	52
14	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Lancet Infectious Diseases</i> , The, 2022, 22, 636-648.	4.6	52
15	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
16	Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 712122.	2.2	43
17	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
18	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1061-1070.	4.6	36

#	ARTICLE	IF	CITATIONS
19	Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax. <i>Journal of Infectious Diseases</i> , 2010, 201, 1353-1360.	1.9	35
20	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	1.9	35
21	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	1.9	28
22	Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. <i>Vaccine</i> , 2009, 27, 4990-5000.	1.7	26
23	First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). <i>Journal of Infectious Diseases</i> , 2014, 210, 1052-1061.	1.9	25
24	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	3.9	20
25	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq1 2.0.7843149rgBT /Ov	2.0	14
26	Clindamycin-resistant <i>Streptococcus pyogenes</i> : report of a case. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 223-225.	0.8	11
27	Uremic Frost. <i>New England Journal of Medicine</i> , 2005, 352, e13.	13.9	10
28	Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. <i>Vaccine</i> , 2012, 31, 114-119.	1.7	10
29	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
30	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
31	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
32	Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab504.	0.4	5
33	Vaccinia Folliculitis After Primary Dryvax Vaccination. <i>Infectious Diseases in Clinical Practice</i> , 2007, 15, 132-134.	0.1	3
34	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa606.	0.4	2
35	Hepatitis E Virus. , 2015, , 2131-2141.e3.		1
36	A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes. <i>BMC Infectious Diseases</i> , 2021, 21, 802.	1.3	0

#	ARTICLE	IF	CITATIONS
37	100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant. <i>Open Forum Infectious Diseases</i> , 2021, 8, S63-S63.	0.4	0